Blue Matter Blog

The Complex Oncology Audience
December 13, 2018

Part Three in a Six-Part Series on Oncology Product Commercialization In Part One of this series, we outlined five commercial challenges in oncology that biopharma decision-makers must face.  Part Two dealt with the first of those challenges, the “constant state of launch” that now exists in oncology.  In this installment, we introduce the complex array …

The Disruptive Potential of Gene Therapy: When will it fully realize its commercial potential?
December 7, 2018

Gene therapy has made significant advances over the past few years.  However, those therapeutic advances have not been accompanied by spectacular commercial successes, at least not yet.  This raises a simple question: When will gene therapy fully realize its commercial potential? We explored that question with a distinguished panel on November 7, 2018 at the …

Dealing with the Constant State of Launch in Oncology
November 7, 2018

Part Two in a Six-Part Series on Oncology Product Commercialization In Part One, we mentioned that the launch frequency for oncology products has increased significantly over the last several years.  While this trend is seen in other therapeutic areas across the industry, we believe the combination of factors driving this in oncology are somewhat unique …

Solving Oncology Commercialization Challenges
Key Commercial Challenges in Oncology
September 20, 2018

Part One in a Six-Part Series on Oncology Product Commercialization The oncology market continues to grow at a phenomenal pace, with worldwide revenues expected to increase from $104B in 2017 to $233B in 20241. Fueling this revenue growth is a rich pipeline, with more than 700 molecules in late-stage development – a 60% increase from …

Demonstrating the Value of Rare Disease Treatments
July 25, 2018

Part V in a Series on Rare Diseases At various points in this series, we’ve mentioned that rare disease treatments are usually quite expensive.  In fact, the typical RD treatment costs between $300,000 and $750,000 (US) per year.1 Those high costs reflect two key realities:  1.) Developing new therapies is expensive and risky, and 2.) …

Organizing to Enable the “High-Touch” Rare Disease Business Model
June 27, 2018

Part IV in a Series on Rare Diseases In Part I of this series, we introduced the fact that rare disease (RD) patients are quite special.  The same is true for the specialists who treat them.  In RD markets, these dynamics create the need for patient-centric treatment approaches and a “high-touch” business model with key …

Rare Disease Centers of Excellence
June 13, 2018

Part III in a Series on Rare Diseases In parts I and II of this series, we provided an overview of the special commercial challenges associated with rare disease (RD) therapies, and we took a deeper dive into one of the most obvious:  Finding patients.   In this installment, we explore rare disease Centers of Excellence …

Finding Patients: A Key Challenge in Rare Diseases
May 30, 2018

Part 2 in a Series on Rare Diseases Part 1 of this series provided an overview of rare diseases and the special challenges they present to biopharmaceutical companies.  In this installment, we explore one of the most basic—and most confounding—of those challenges:  Finding patients. In the European Union, a disease is considered rare when it …

Blue Matter Academy: Investing in Learning
May 25, 2018

Blue Matter Academy (BMA) is Blue Matter Consulting’s in-house learning and development organization.  Officially launched in 2017, BMA’s goal is to provide ongoing learning opportunities for all Blue Matter team members.  Recently, Karen Foster, Learning Strategist and Head of Blue Matter Academy, took the time to answer some common questions about the Academy and Blue …

9th European Conference on Rare Diseases and Orphan Products
ECRD Vienna 2018 Recap
May 15, 2018

Recently (10-12 May), we traveled to Vienna to attend the 9th European Conference on Rare Diseases and Orphan Products (ECRD).  In this article, we describe some of the key takeaways from the conference, and the major implications for biopharmaceutical companies operating in this space. Our Focus on Rare Diseases More than 7,000 diseases are classified …

We use cookies to provide website functionality and give you the best possible experience. Our Cookie Statement provides more information and explains how to amend your cookie settings.

By pressing the “Accept Cookies” button, the user accepts all Cookies on the Website. View our Cookie Statement.